For the quarter ending 2026-03-31, RVPH had $7,751,439 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,195,987 | -3,367,679 | -4,010,773 | -12,486,450 |
| Change in fair value of warrant liabilities | 0 | -44,506 | 27,816 | -72,320 |
| Stock-based compensation expense | 584,439 | 455,084 | 458,379 | 1,314,396 |
| Prepaid clinical trial costs (current and non-current) | 0 | -81,742 | -22,705 | -436,154 |
| Prepaid expenses and other current assets | -36,251 | 416,758 | -99,037 | -319,471 |
| Accounts payable | -976,347 | -2,197,246 | 325,332 | -1,535,859 |
| Accrued expenses and other current liabilities | -249,652 | -308,848 | -2,511,982 | -1,182,338 |
| Net cash used in operating activities | -3,801,296 | -5,798,211 | -5,589,486 | -13,206,946 |
| Proceeds from issuance of short-term debt | - | 406,875 | 0 | 0 |
| Repayment of short-term debt | 175,601 | 0 | 113,246 | 344,908 |
| Proceeds from issuance of common stock in atm offering, net of transaction costs-The Market Offering Agreement Atm Agreement | 2,535,337 | 176,721 | 312,574 | 988,112 |
| Proceeds from issuance of common stock, common stock warrants, and prefunded warrants in offerings, net of transaction costs paid | 9,192,991 | -264,792 | 8,209,703 | 9,210,000 |
| Proceeds from exercise of common stock warrants-Common Stock Warrants | 8 | 6,734,940 | 0 | 241,125 |
| Net cash provided by financing activities | 11,552,735 | 7,053,744 | 8,409,031 | 10,094,329 |
| Net increase (decrease) in cash and cash equivalents | 7,751,439 | 1,255,533 | 2,819,545 | -3,112,617 |
| Cash and cash equivalents, beginning of period | 14,438,792 | 13,183,259 | 13,476,331 | - |
| Cash and cash equivalents, end of period | 22,190,231 | 14,438,792 | 13,183,259 | - |
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)